Literature DB >> 23072840

Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer.

Saverio Alberti1, Federico Ambrogi, Patrizia Boracchi, Marco Fornili, Patrizia Querzoli, Massimo Pedriali, Rossana La Sorda, Rossano Lattanzio, Romina Tripaldi, Mauro Piantelli, Elia Biganzoli, Danila Coradini.   

Abstract

OBJECTIVE: Trop-1/Ep-CAM modulates growth and survival of transformed cells, and it is highly expressed in most carcinomas including breast cancer. Only membranous staining is typically considered in evaluating Trop-1/epithelial cell adhesion molecule (Ep-CAM) expression in tumor cells. However, there is evidence of retention of Trop-1/Ep-CAM, as functionally incompetent molecules, in intra-cytoplasmic vesicles. Hence, we investigated whether cytoplasmic immunostaining may have an independent clinical significance with respect to membranous staining.
METHODS: Membranous and cytoplasmic Trop-1/Ep-CAM expression was immunohistochemically investigated in 642 unilateral breast cancers from patients with a 99-month median follow-up. Multiple correspondence analysis was used to investigate the association between Trop-1/Ep-CAM and other biological variables. The impact of Trop-1/Ep-CAM expression on the patient's outcome was evaluated as event-free survival by the Kaplan-Meier method and proportional hazard Cox model.
RESULTS: While tumors with intermediate/strong membranous staining were mostly associated with concomitant cytoplasmic Trop-1/Ep-CAM expression (97%), tumors with weak-to-nil membranous staining showed intermediate/high cytoplasmic expression in 23% of cases. Cytoplasmic overexpression was associated with a favorable outcome, especially in node-positive patients, regardless of the adjuvant therapy received.
CONCLUSION: Trop-1/Ep-CAM expression may have different clinical implications according to its subcellular localization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072840     DOI: 10.1093/jjco/hys159

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy.

Authors:  Guihong Wang; Zhenhua Zhang; Yongqiang Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 2.  Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences.

Authors:  Olivier Gires; Nikolas H Stoecklein
Journal:  Cell Mol Life Sci       Date:  2014-08-08       Impact factor: 9.261

3.  Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection.

Authors:  Yao Meng; Bao-Qing Xu; Zhi-Guang Fu; Bo Wu; Bo Xu; Zhi-Nan Chen; Ling Li
Journal:  Int J Clin Exp Med       Date:  2015-12-15

4.  Using DNA aptamer probe for immunostaining of cancer frozen tissues.

Authors:  Ying Pu; Zhenxu Liu; Yi Lu; Peng Yuan; Jun Liu; Bo Yu; Guodong Wang; Chaoyong James Yang; Huixia Liu; Weihong Tan
Journal:  Anal Chem       Date:  2015-01-16       Impact factor: 6.986

5.  p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.

Authors:  Emanuela Guerra; Alessia Cimadamore; Pasquale Simeone; Giovanna Vacca; Rossano Lattanzio; Gerardo Botti; Valentina Gatta; Marco D'Aurora; Barbara Simionati; Mauro Piantelli; Saverio Alberti
Journal:  BMC Cancer       Date:  2016-08-18       Impact factor: 4.430

6.  Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.

Authors:  Dominic Fong; Andreas Seeber; Luigi Terracciano; Armin Kasal; Guido Mazzoleni; Florian Lehne; Guenther Gastl; Gilbert Spizzo
Journal:  J Clin Pathol       Date:  2014-01-24       Impact factor: 3.411

7.  Trop-2 is a determinant of breast cancer survival.

Authors:  Federico Ambrogi; Marco Fornili; Patrizia Boracchi; Marco Trerotola; Valeria Relli; Pasquale Simeone; Rossana La Sorda; Rossano Lattanzio; Patrizia Querzoli; Massimo Pedriali; Mauro Piantelli; Elia Biganzoli; Saverio Alberti
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.